成人小说亚洲一区二区三区,亚洲国产精品一区二区三区,国产精品成人精品久久久,久久综合一区二区三区,精品无码av一区二区,国产一级a毛一级a看免费视频,欧洲uv免费在线区一二区,亚洲国产欧美中日韩成人综合视频,国产熟女一区二区三区五月婷小说,亚洲一区波多野结衣在线

立即打開
Amgen's DMab scores in trials

Amgen's DMab scores in trials

2009年07月10日

????For the biotech, a new drug for bone cancer and osteoporosis could mean a big boost in revenue.

????By Alyssa Abkowitz

????An Amgen trial drug -- called denosumab -- reached a new milestone on July 7 when the biotechnology company announced results from the latest clinical trial of the drug for bone cancer. The trial of more than 2,000 patients showed DMab -- which works to slow bone destruction, a primary concern for people with advanced cancer and the cause of a myriad of complications, including fractures -- delayed the time it took for damage to occur when compared to rival drug Zometa, which is made by Novartis. Amgen has already submitted DMab to the Food and Drug Administration as a treatment for osteoporosis.

????"We're very, very excited about it," Amgen CEO Kevin Sharer told Fortune. "This has been a drug we've worked on for 15 years. We did the fundamental biology and invested over $1 billion. I bet my job on it."

????Yesterday, the day after the announcement, Amgen's stock surged 14% -- the most in four years. Analysts had a field day in their notes, with some increasing Amgen's share price expectations to more than $70 and others upping annual revenue estimates for DMab to as high as $3 billion.

????Steve Yoo, an analyst at health care investment bank Leerink Swann, estimated in a note that U.S. sales of DMab as a treatment for bone cancer could hit $558 million by 2012. And U.S. sales of the drug as an osteoporosis therapy could total more than $2 billion in the same period, for an overall DMab revenue of more than $3 billion by Yoo's calculations.

????By comparison, Zometa brought in $1.4 billion in sales last year. Yoo noted that the cost of DMab will likely be higher than Zometa, but warned that pricing it too high could limit prescriptions of the drug as an osteoporosis treatment.

????DMab is a biologic -- a medicine made from living organisms -- and works by blocking the activity of the protein that regulates the cells responsible for breaking down bone, making it valuable as an osteoporosis therapy. When used as a bone cancer treatment, it targets metastases that are extremely prevalent with certain types of advanced cancer, reaching incident rates of nearly 75% in breast and prostate cancer patients, according to Amgen (AMGN, Fortune 500).

????The biotech expects an FDA decision on DMab as an osteoporosis therapy by Oct. 19. Yoo says there's no timeline yet on when the drug will be submitted to the agency for approval as a bone cancer treatment. But whenever the decisions arrive, approval of DMab for both uses would mean a big boost for Amgen. "I think it'll really be important for patients," Sharer told Fortune. "So it's very, very important to us."

掃碼打開財(cái)富Plus App
亚洲男人的天堂久久无在线观看免费黄视频| 久久婷婷五月综合色国产香蕉| 亚洲人成网址在线播放狼友| 国产午夜亚洲精品一级在线| 凹凸在线无码免费视频| 日韩欧美精品一本二本道一区| 国产欧美日韩亚洲18禁在线| 亚洲AV一宅男色影视| H动漫无遮挡成本人H视频| 白丝美女被狂躁免费视频网站| 亚洲国产tv在线观看| 一级作爱视频免费观看 | 在线看黄Ⅴ免费网站免费看| 黄色一级网站国产成人毛片| 精品久久福利一区二区| 日本中文一区二区三区亚洲| 产成a人亚洲精v品无码| 日韩一区二区精品蜜桃视频| 亚洲激情网五月婷婷久久| 亚洲日韩国产欧美一区二区三区| 国产 中文 制服丝袜 另类精品人妻| 密桃A∨秘无码一区二区三区| 久久综合九色综合97首页| 日韩精品无码一区二区| 99久久国产精品免费一区二区| 欧美极品JIZZHD欧美| 久久国产亚洲日韩一本| 国产乱人伦App精品久久| 国产成人一区二区三区视频免费| 人妻少妇精品视频一区二区三区| 99久久久国产精品免费牛牛| 国产精品秘 入口久久熟女| 亚洲乱码专区一区二区三区| 光棍影院一级毛片视频| 国产日产亚洲系列最新美| 无码精品一区二区三区在线| 无码高潮喷水在线播放观看| 国产高清av在线免费观看一区二区| 无遮挡h纯内动漫在线观看| 久久亚洲AV无码西西人体| 虎白女粉嫩在线观看视频一线天|